Skip to main content

Avantor, Inc. (AVTR) Stock Analysis

Range Bound setup

SellModerate Confidence

Healthcare · Medical Instruments & Supplies

Sell if holding. Engine safety override at $7.96: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.91; Below-average business quality; Negative price momentum.

Avantor is a global provider of mission-critical products and services to biopharma, education/government, and advanced technology markets through two segments: Laboratory Solutions (VWR distribution channel) and Bioscience Production (specialty manufacturing). The company... Read more

$7.96+15.7% A.UpsideScore 5.2/10#15 of 25 Medical Instruments & Supplies
Stop $7.40Target $9.20(analyst − 13%)A.R:R 1.5:1
Analyst target$10.58+32.9%13 analysts
$9.20our TP
$7.96price
$10.58mean
$19

Sell if holding. Engine safety override at $7.96: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.91; Below-average business quality; Negative price momentum. Chart setup: RSI 45 mid-range, Bollinger mid-band. Score 5.2/10, moderate confidence.

Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 91d clear, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.

Thesis

Rewards
No bull case signals
Risks
Quality below floor (3.4 < 4.0)

Key Metrics

P/E (TTM)
P/E (Fwd)9.5
Mkt Cap$5.5B
EV/EBITDA9.5
Profit Mgn-8.4%
ROE-9.4%
Rev Growth0.0%
Beta1.00
DividendNone
Rating analysts25

Quality Signals

Piotroski F8/9

Options Flow

P/C2.91bearish
IV53%elevated
Max Pain$30+276.9% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMSuppliersole-sourced raw materials
    10-K Item 1A: 'many of which are sole-sourced due to market or customer demands'

Material Events(8-K, last 90d)

  • 2026-04-01Item 5.02HIGH
    CFO R. Brent Jones resigned to join a company outside the life sciences industry; 90-day notice required. Steven Eck (SVP, Chief Accounting Officer) named interim CFO pending permanent search. No permanent successor named.
    SEC filing →
  • 2026-04-23Item 5.02MEDIUM
    Benoit Gourdier (EVP, Bioscience and Medtech Products) transitioning to a supporting role, expected to depart by December 31, 2026. Ludovic Brellier hired as new EVP effective May 1, 2026. Clean handoff with named successor.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers·1 ceiling hit

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume
0.0
Obv
1.0
Ma Position
1.0
Macd
3.9
Rsi
4.5
Volume distribution (falling OBV)Below 200-MA, MA slope -6.8%/30d — confirmed downtrend

Unprofitable operations — net margin -8.4%. Quality floor flags this regardless of sector context.static

Roe
0.0
Net Margin
0.0
Roa
1.9
Gross Margin
2.4
Operating Margin
2.5
Moat
5.0
Current Ratio
6.3
Piotroski F
8.9
No competitive moatStrong Piotroski F-Score: 8/9

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Erm
1.0
Earnings History
1.1
Surprise Avg
3.1
Earnings Timing
5.0
News Activity
8.0
Estimates down -15.3% (30d)Earnings concerns: 1B/2M

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
1.5
Growth Rank
5.0
Value Rank
8.8
GatesMomentum 2.1<4.5Death cross (50MA < 200MA)A.R:R 1.5 ≥ 1.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY 91d clearSEMI CYCLE PEAK CLEARRange BoundSuitability: Moderate
RSI
45 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $7.46Resistance $8.85

Price Targets

$7
$9
A.Upside+15.6%
A.R:R1.5:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (3.4 < 4.0)
! Momentum score 2.1/10 — below 4.5 minimum
! Death cross — 50-day MA below 200-day MA

Earnings

B
M
M
M
1/4 beats
Next Earnings2026-07-31 (91d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is AVTR stock a buy right now?

Sell if holding. Engine safety override at $7.96: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.91; Below-average business quality; Negative price momentum. Chart setup: RSI 45 mid-range, Bollinger mid-band. Prior stop was $7.40. Score 5.2/10, moderate confidence.

What is the AVTR stock price target?

Take-profit target: $9.20 (+15.7% upside). Prior stop was $7.40. Stop-loss: $7.40.

What are the risks of investing in AVTR?

Quality below floor (3.4 < 4.0).

Is AVTR overvalued or undervalued?

Avantor, Inc. trades at a P/E of N/A (forward 9.5). TrendMatrix value score: 8.6/10. Verdict: Sell.

What do analysts say about AVTR?

25 analysts cover AVTR with a consensus score of 2.8/5. Average price target: $11.

What does Avantor, Inc. do?Avantor is a global provider of mission-critical products and services to biopharma, education/government, and advanced...

Avantor is a global provider of mission-critical products and services to biopharma, education/government, and advanced technology markets through two segments: Laboratory Solutions (VWR distribution channel) and Bioscience Production (specialty manufacturing). The company serves more than 300,000 customer locations in approximately 180 countries with more than 85% of net sales from recurring offerings.

Related stocks: WST (West Pharmaceutical Services, I) · MMSI (Merit Medical Systems, Inc.) · RMD (ResMed Inc.) · STVN (Stevanato Group S.p.A.) · ATRC (AtriCure, Inc.)